Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The airway lining fluid (ALF) biophysical barrier is a dynamic, multi-layered interface covering the respiratory epithelium from the upper airways down to the alveoli (Bustamante-Marin & Ostrowski, 2017). It primarily consists of the airway surface liquid (ASL), which is composed of a low-viscosity periciliary liquid layer that facilitates ciliary beating and an overlying high-viscosity mucus layer that traps inhaled particulates (Fahy & Dickey, 2010). Its fundamental biological function is to serve as the first line of innate defense, providing chemical, physical, and biological protection against pathogens and toxins through mucociliary clearance and the presence of antimicrobial proteins (NIH, PubMed). In the alveolar region, the ALF includes the pulmonary surfactant system, which is essential for reducing surface tension and preventing alveolar collapse during expiration (StatPearls, Lung Surfactant). Dysfunction of this barrier, such as mucus dehydration or surfactant depletion, is a central pathological feature in diseases like cystic fibrosis, COPD, and ARDS (Agudelo et al., 2020). Therapeutic strategies target the ALF by modifying its biophysical properties—using mucolytics to thin secretions, hypertonic solutions to improve hydration, or surfactants to restore lung compliance. Furthermore, the ALF represents a significant pharmacokinetic hurdle for inhaled drug delivery, as medications must penetrate this barrier to reach the underlying cellular targets (NIH).
Modification of mucus rheology and viscosity via disulfide bond reduction or DNA degradation; restoration of alveolar surface tension via exogenous surfactant replacement; enhancement of periciliary fluid volume through osmotic hydration.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Airway lining fluid biophysical barrier (ALF).